|
|
40
|
|
|
4181BE
|
|
|
KEYTRUDA 25MG/ML INJ (MSD/STO) PEMBROLIZUMAB
|
|
|
PEMBROLIZUMAB
|
|
|
KEYTRUDA
|
|
|
4ML VIAL
|
|
|
C
|
|
|
9,766.50
|
|
|
9,766.50
|
|
|
25MG/ML
|
|
|
INJECTION
|
|
|
0
|
|
|
VIAL
|
|
|
MSD
|
|
|
MERCK SHARP & DOHME (I.A.) CORP
|
|
|
STO
|
|
|
BRYDEN STOKES LTD
|
|
|
|
|
|
Anti-Neoplastic
|
|
|
2022-04-01
|
|
|
2024-03-31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No
|
|
|
1000
|
|
|
ANTINEOPLASTICS
|
|
|
|
|
|
IV
|
|
|
0
|
|
|
ANTINEOPLASTICS
|
|
|
|